home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

New Approach for Leukaemia Treatment?

  September, 18 2008 7:01
your information resource in human molecular genetics

Drugs that block the action of an enzyme called glycogen synthase kinase (GSK3) may prove useful in treating a particular type of poor prognosis leukaemia, suggests a study published online in Nature.

Michael Cleary and colleagues focused on a subtype of leukaemia characterized by alterations in the MLL gene, which accounts for up to 10% of sporadic leukaemias in adults and children. Mice with a version of the cancer and treated with the GSK3 inhibitor lithium carbonate lived significantly longer than placebo-treated controls. And in vitro, a different GSK3 inhibitor stopped MLL leukaemia cells from proliferating.

GSK3 is involved in many different signalling pathways, and GSK3 inhibitors are currently being tested as therapies for different diseases, including Alzheimer's. The current findings are at odds with previous studies, which show that GSK3 can suppress cancer-linked signalling pathways. So the results highlight an unexpected and intriguing potential anti-cancer role for GSK3 inhibitors.


Michael Cleary (Stanford University School of Medicine, CA, USA)
E-mail: mcleary@stanford.edu

Abstract available online.

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.